GlassScriptPhysician profile
Shaista A Quddusi
NPI 1053340885
$4,185.42
in general payments reported to CMS, 2019-2025
25 companies · $380 in 2025
The $380 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $604 · 2020: $16.73 · 2021: $144 · 2022: $778 · 2023: $481 · 2024: $1,782 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,963 · Travel and Lodging: $680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,962.84 |
| Travel and Lodging | $679.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,183.24 | 2021-2024 | Minimed 780g |
| Lilly USA, LLC | $547.44 | 2021-2024 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $357.86 | 2019-2022 | |
| Abbott Laboratories | $335.36 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $282.75 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $197.44 | 2019-2022 | |
| Dexcom, INC. | $197.20 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $186.47 | 2022-2024 | |
| Tandem Diabetes Care, INC. | $173.48 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $135.26 | 2025 | |
| Xeris Pharmaceuticals, INC. | $129.87 | 2022-2024 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $71.43 | 2024 | Korlym |
| Mannkind Corporation | $68.53 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $58.39 | 2024 | |
| Insulet Corporation | $50.97 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $30.07 | 2019 | |
| Sanofi-Aventis U.S. LLC | $25.62 | 2023 | |
| Novartis Pharmaceuticals Corporation | $24.80 | 2024 | |
| Radius Health, INC. | $23.18 | 2022 | |
| Ascensia Diabetes Care US INC. | $22.80 | 2024 | |
| Amgen INC. | $20.42 | 2019 | |
| Esperion Therapeutics, INC. | $18.65 | 2024 | Nexletol |
| Allergan, INC. | $15.83 | 2021 | |
| Cequr Corporation | $15.49 | 2022 | |
| Antares Pharma, INC. | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaista Quddusi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.